Citation Report

List of articles citing

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS

DOI: 10.1002/pros.22686
Prostate, 2013, 73, 1391-402.

#	Paper	IF	Citations
94	Risks and benefits of late onset hypogonadism treatment: an expert opinion. *World Journal of Men?s Health*, **2013**, 31, 103-25	6.8	69
93	Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. *International Journal of Endocrinology*, **2014**, 2014, 329456	2.7	77
92	Editorial comment on Zhang et al.: Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. *Urologia Internationalis*, **2014**, 93, 247-8	1.9	
91	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. *Nature Reviews Urology*, **2014**, 11, 231-41	5.5	26
90	Acute effects of physical exercise and phosphodiesterase‐5 type 5 inhibition on serum 11‐hydroxysteroid dehydrogenases related glucocorticoids metabolites: a pilot study. *Endocrine*, **2014**, 47, 952-8	4	7
89	Benign prostatic hyperplasia: a new metabolic disease?. *Journal of Endocrinological Investigation*, **2014**, 37, 313-22	5.2	104
88	Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. *Journal of Sexual Medicine*, **2014**, 11, 2074-82	1.1	34
87	Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice. *Tissue and Cell*, **2014**, 46, 439-49	2.7	6
86	Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?. *BJU International*, **2014**, 113, 694-5	5.6	5
85	Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. *Drugs and Aging*, **2014**, 31, 425-39	4.7	10
84	Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. *Prostate*, **2015**, 75, 233-41	4.2	28
83	The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. *Journal of Inflammation*, **2015**, 12, 54	6.7	23
82	Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. *International Journal of Clinical Practice*, **2015**, 69, 1496-507	2.9	11
81	Recent advances in treatment for Benign Prostatic Hyperplasia. *F1000Research*, **2015**, 4,	3.6	8
80	Testosterone and benign prostatic hyperplasia. *Asian Journal of Andrology*, **2015**, 17, 212-6	2.8	33
79	A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. *Expert Opinion on Investigational Drugs*, **2015**, 24, 1059-73	5.9	7
78	Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. *International Journal of Urology*, **2015**, 22, 982-90	2.3	29

77	Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (LUTS): A New Target for Pharmacological Treatment?. *LUTS: Lower Urinary Tract Symptoms*, **2015**, 7, 1-8	1.9	26
76	Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release. *European Journal of Pharmacology*, **2015**, 754, 92-7	5.3	13
75	Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. *World Journal of Urology*, **2015**, 33, 743-51	4	19
74	Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. *Aging Male*, **2015**, 18, 207-16	2.1	24
73	Benign prostatic hyperplasia and metabolic syndrome: the expanding evidences of a new disease of aging male. *Aging Male*, **2015**, 18, 133-4	2.1	10
72	Long-term phosphodiesterase 5 inhibitor administration reduces inflammatory markers and heat-shock proteins in cavernous tissue of Zucker diabetic fatty rat (ZDF/fa/fa). *International Journal of Impotence Research*, **2015**, 27, 182-90	2.3	10
71	Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. *BJU International*, **2015**, 115, 24-31	5.6	141
70	Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. *Translational Andrology and Urology*, **2016**, 5, 450-9	2.3	11
69	Inflammatory mediators in the development and progression of benign prostatic hyperplasia. *Nature Reviews Urology*, **2016**, 13, 613-26	5.5	109
68	Antimuscarinics, ⊟ Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm. *Urologic Clinics of North America*, **2016**, 43, 337-49	2.9	3
67	The role of prostate inflammation and fibrosis in lower urinary tract symptoms. *American Journal of Physiology - Renal Physiology*, **2016**, 311, F817-F821	4.3	27
66	Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *European Urology*, **2016**, 70, 124-133	10.2	85
65	Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits. *Molecular and Cellular Endocrinology*, **2016**, 424, 50-70	4.4	19
64	Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients. *World Journal of Urology*, **2016**, 34, 1183-92	4	13
63	Antioxidant Potential and Ability of Phloroglucinol to Decrease Formation of Advanced Glycation End Products Increase Efficacy of Sildenafil in Diabetes-Induced Sexual Dysfunction of Rats. *Sexual Medicine*, **2016**, 4, e104-12	2.7	23
62	Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. *Journal of Endocrinological Investigation*, **2016**, 39, 143-51	5.2	22
61	The regulation of transient receptor potential canonical 4 (TRPC4) channel by phosphodiesterase 5 inhibitor via the cyclic guanosine 3$5Smonophosphate. *Pflugers Archiv European Journal of Physiology*, **2017**, 469, 693-702	4.6	4
60	[Bladder storage and voiding dysfunctions : Side effects of drug therapy]. *Der Urologe*, **2017**, 56, 456-464		2

59	Relation between histological prostatitis and lower urinary tract symptoms and erectile function. *Prostate International*, **2017**, 5, 119-123	3.4	5
58	Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3$5Smonophosphate pathway. *International Journal of Urology*, **2017**, 24, 412-424	2.3	6
57	Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. *BMC Urology*, **2017**, 17, 22	2.2	19
56	Emerging drugs for the treatment of benign prostatic hyperplasia. *Expert Opinion on Emerging Drugs*, **2017**, 22, 201-212	3.7	11
55	The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. *Asian Journal of Urology*, **2017**, 4, 158-163	2.7	13
54	The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction. *Neurourology and Urodynamics*, **2017**, 36, 1479-1487	2.3	3
53	The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction. *Therapeutic Advances in Urology*, **2017**, 9, 11-27	3.2	61
52	The effect of tadalafil therapy on kidney damage caused by sepsis in a polymicrobial septic model induced in rats: a biochemical and histopathological study. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2017**, 43, 345-355	2	9
51	Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. *Singapore Medical Journal*, **2017**, 58, 473-480	1.9	8
50	Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study). *BJU International*, **2018**, 122, 317-325	5.6	7
49	Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis. *Prostate*, **2018**, 78, 707-713	4.2	18
48	Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia. *Future Science OA*, **2018**, 4, FSO304	2.7	3
47	Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 161-167	6.2	6
46	Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). *LUTS: Lower Urinary Tract Symptoms*, **2018**, 10, 76-83	1.9	4
45	Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms (MIPS Study). *BJU International*, **2018**, 121, 799-804	5.6	11
44	Metabolic Syndrome and LUTS/BPH. **2018**, 89-111		0
43	Efficacy and safety of PDE5-Is and 1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs. *BMC Urology*, **2018**, 18, 30	2.2	5
42	Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia. *Molecular and Clinical Oncology*, **2018**, 9, 302-304	1.6	7

41	Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study. *World Journal of Urology*, **2019**, 37, 867-872	4	12
40	Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?. *Current Urology Reports*, **2019**, 20, 54	2.9	19
39	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. *Journal of Clinical Medicine*, **2019**, 8,	5.1	7
38	A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. *BMC Urology*, **2019**, 19, 99	2.2	8
37	The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health. *Current Urology Reports*, **2019**, 20, 58	2.9	4
36	Tadalafil for the treatment of benign prostatic hyperplasia. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 929-937	4	12
35	Toward a Scientific Nutritional Supplement Combination for Prostatism and Erectile Dysfunction I: From Known Pharmacology to Clinical Testing. *Journal of Medicinal Food*, **2019**, 22, 529-537	2.8	1
34	The association between local arteriosclerosis of the prostatic arteries and chronic inflammation in human benign prostatic enlargement. *Prostate*, **2019**, 79, 574-582	4.2	5
33	Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 T cells in benign prostatic hyperplasia. *Prostate*, **2019**, 79, 909-919	4.2	10
32	Tadalafil Treatment Improves Inflammation, Cognitive Function, And Mismatch Negativity Of Patients With Low Urinary Tract Symptoms And Erectile Dysfunction. *Scientific Reports*, **2019**, 9, 17119	4.9	11
31	Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation. *Pharmaceutics*, **2019**, 11,	6.4	14
30	Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients. *Journal of Clinical Urology*, **2019**, 12, 223-227	0.2	1
29	Sildenafil, a phosphodiesterase type 5 inhibitor, augments sphincter bursting and bladder afferent activity to enhance storage function and voiding efficiency in mice. *BJU International*, **2019**, 124, 163-173	5.6	6
28	Editorial Comment from Dr Tanaka to Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. *International Journal of Urology*, **2020**, 27, 58-59	2.3	
27	Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. *International Journal of Urology*, **2020**, 27, 53-57	2.3	11
26	Add-on effects of tadalafil in tamsulosin-treated patients with small benign prostatic enlargement: A randomized, placebo-controlled, double-blind, crossover study. *Neurourology and Urodynamics*, **2020**, 39, 237-242	2.3	2
25	Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 13181-13195	5.6	2
24	Effect and mechanism of prophylactic use of tadalafil during pregnancy on l-NAME-induced preeclampsia-like rats. *Placenta*, **2020**, 99, 35-44	3.4	3

23	Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. *Current Urology Reports*, **2020**, 21, 56	2.9	11
22	Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). *Urologia Internationalis*, **2020**, 104, 587-593	1.9	4
21	Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. *World Journal of Urology*, **2020**, 38, 2771-2779	4	16
20	Higher expression of phosphodiesterase type 5 in the anterior fibromuscular stroma of the human prostate. *World Journal of Urology*, **2020**, 38, 2915-2921	4	0
19	Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. *Biomedicine and Pharmacotherapy*, **2021**, 134, 111128	7.5	15
18	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. *European Urology Focus*, **2021**, 7, 432-439	5.1	2
17	Bladder Outlet Obstruction and Overactive Bladder in Males. *Urodynamics, Neurourology and Pelvic Floor Dysfunctions*, **2021**, 67-85	0.1	
16	Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial. *International Journal of Urology*, **2021**, 28, 432-438	2.3	1
15	Lower urinary tract symptoms, erectile dysfunction, and their correlation in men aged 50 years and above: a cross-sectional survey in Beijing, China. *Medical Science Monitor*, **2014**, 20, 2806-10	3.2	12
14	Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia. *Aging*, **2019**, 11, 1524-1536	5.6	3
13	Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. *Asian Journal of Andrology*, **2014**, 16, 767-73	2.8	8
12	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. *Asian Journal of Andrology*, **2016**, 18, 723-31	2.8	8
11	Non-Hormonal treatment of BPH/BOO. *Indian Journal of Urology*, **2014**, 30, 194-201	0.8	1
10	Antinociceptive Effect of Vardenafil on Carrageenan-Induced Hyperalgesia in Rat: involvement of Nitric Oxide/Cyclic Guanosine Monophosphate/Calcium Channels Pathway. *Iranian Journal of Pharmaceutical Research*, **2015**, 14, 1137-43	1.1	5
9	Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure.. *Life Sciences*, **2021**, 289, 120237	6.8	1
8	Use of a Fission Yeast Platform to Identify and Characterize Small Molecule PDE Inhibitors.. *Frontiers in Pharmacology*, **2021**, 12, 833156	5.6	
7	Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. *Minerva Urology and Nephrology*, **2022**, 73,	2.3	0
6	Benign Prostatic Hyperplasia/Obstruction Ameliorated Using a Soluble Guanylate Cyclase Activator.. *Journal of Pathology*, **2021**,	9.4	0

5	Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial.. *Journal of Endocrinological Investigation*, **2022**,	5.2	
4	Efficacy Evaluation of Plant Products in the Treatment of Erectile Dysfunction Related to Diabetes.. *Nutrients*, **2021**, 13,	6.7	1
3	Ligand-Enhanced Negative Images Optimized for Docking Rescoring. *International Journal of Molecular Sciences*, **2022**, 23, 7871	6.3	1
2	Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study. **2022**, 65, 231-237		0
1	A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia. **2023**, 12, 1821		0